Noxopharm (ASX:NOX) said it has raised nearly AU$2.5 million in non-dilutive funding by selling its entire stake in Biotechnolgy company Nyrada (ASX:NYR), according to a Tuesday filing with the Australian bourse.
The proceeds will be used to launch the upcoming Heracles clinical trial and invest in research and development, the filing said.